In a phase 2 trial published Oct. 26, 2026, in Cell Metabolism, UBT251, a weekly shot that acts on three gut hormones, lowered HbA1c by up to 2.16% at 24 weeks in…
In older US adults with fatty liver disease, starting a GLP-1 drug was linked to lower risks of liver decompensation (hazard ratio 0.72) and death (0.55), but not of major heart events,…
In a study of US dialysis patients with diabetes published Oct. 27, 2026, in Diabetes Care, semaglutide users had a 1-year death rate of 11% vs. 13% with dulaglutide or liraglutide, and…
